Overview

TYPE 2 HEPATORENAL SYNDROME

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Various vasoconstrictors have shown promising results in the management of type 1 hepatorenal syndrome (HRS). However, there are very few studies on vasopressors in the management of type 2 HRS. Terlipressin has been used commonly; however it is costly and not available in some countries. In the present study, the investigators evaluated safety and efficacy of terlipressin and noradrenaline in the treatment of type 2 HRS
Phase:
Phase 3
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research
Treatments:
Lypressin
Norepinephrine
Terlipressin